Mark Wildgust: Outstanding Results from the FLAIR Study Presented at EHA25
Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on X:
“Outstanding results from the FLAIR study presented at EHA25 today and published in the NEJM.”
Title: Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
Journal: NEJM
Authors: Talha Munir, Sean Girvan, David A. Cairns, Adrian Bloor, David Allsup, Abraham M. Varghese, Satyen Gohil, Shankara Paneesha, Andrew Pettitt, Toby Eyre, Christopher P. Fox, Francesco Forconi, Constantine Balotis, Nicholas Pemberton, Oonagh Sheehy, John Gribben, Nagah Elmusharaf, Simona Gatto, Gavin Preston, Anna Schuh, Renata Walewska, Lelia Duley, Nichola Webster, Surita Dalal, Andrew Rawstron, Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sue Bell, David Stones, Julia M. Brown, Piers E.M. Patten, Peter Hillmen
Take a moment to look 25 Posts Not to Miss from EHA 2025
-
Sep 3, 2026, 00:52David Wallace: FDA Approves MIMRYLO to Target Iron Regulation and Reduce Phlebotomy Burden
-
Sep 3, 2026, 00:44Same goal, Different molecular strategy – Which FVIIIa Mimetic Gets There How? – RPTH Journal
-
Sep 3, 2026, 00:33Hannah Isles: Interesting Link between Aging, Serotonin, Platelets and COVID-19 Severity
-
Sep 3, 2026, 00:22Danny Hsu: Paradigm Shift in PE Management? – Unpacking the PRAGUE-26 Trial
-
Sep 3, 2026, 00:14Leonardo Roever: Antiphospholipid Antibodies Present in 19% of Ischemic Stroke Cases
-
Sep 3, 2026, 00:03Jochebed Adwoa Sutherland: First Reported Case of Breast Mondor’s Disease in a Patient Living with Sickle Cell
-
Sep 2, 2026, 23:50Shashank Joshi: Individualized vs. Standard BP Control Shows Similar 90-Day Outcomes
-
Sep 2, 2026, 18:26Strengthening Comprehensive Care for Inherited Bleeding Disorders in Ecuador – World Federation of Hemophilia
-
Sep 2, 2026, 18:24Zeeshan Ahmed Khattak: Managing Febrile Neutropenia in Hematology/Oncology and Transplant Patients